Blood Test Using Extracellular Vesicles Detects Early Colorectal Cancer
New ColonTrack model identifies early-stage colorectal cancer with 94% accuracy using three proteins from blood-based extracellular vesicles.
Summary
Researchers developed ColonTrack, a blood-based diagnostic test that detects colorectal cancer by analyzing proteins in extracellular vesicles. The test achieved 94% sensitivity and 93% specificity in identifying early-stage cancer across 1,272 participants. Using three specific proteins (HNRNPK, CTTN, PSMC6), ColonTrack outperformed existing blood markers and could enable earlier, less invasive screening than current colonoscopy-based approaches.
Detailed Summary
Colorectal cancer remains the third-leading cause of cancer deaths worldwide, with early detection dramatically improving survival rates from 14% to 91%. Current screening methods like colonoscopy are invasive and costly, while blood markers like CEA lack sufficient accuracy for early detection.
Researchers at Fudan University developed a comprehensive approach to identify cancer biomarkers by analyzing extracellular vesicles (EVs) - tiny cellular packages that carry proteins and other molecules between cells. They studied both tumor tissue and blood plasma EVs from 1,272 individuals across multiple medical centers, using advanced mass spectrometry to identify over 5,600 proteins.
The team discovered that three specific proteins (HNRNPK, CTTN, and PSMC6) in blood-based EVs could accurately distinguish colorectal cancer patients from healthy individuals. Their machine learning model, called ColonTrack, achieved remarkable performance: 94% sensitivity, 93% specificity, and an area under the curve greater than 0.97. Importantly, the test performed equally well for early-stage cancers, when treatment is most effective.
ColonTrack outperformed methylated septin-9, a currently available blood test for colorectal cancer, particularly in detecting early-stage disease. The researchers validated their findings across multiple independent cohorts, demonstrating the test's reliability and potential for clinical implementation.
This breakthrough could transform colorectal cancer screening by providing a simple blood test that's more accessible and less invasive than colonoscopy, potentially enabling earlier detection and better outcomes for millions of patients worldwide.
Key Findings
- ColonTrack blood test achieved 94% sensitivity and 93% specificity for colorectal cancer detection
- Three-protein panel (HNRNPK, CTTN, PSMC6) effectively identifies early-stage cancer
- Outperformed existing blood marker methylated septin-9 for early detection
- Validated across 1,272 participants in multiple medical centers
- Extracellular vesicles provide more stable protein targets than conventional blood tests
Methodology
Multi-phase study using mass spectrometry-based protein discovery, parallel reaction monitoring verification, and ELISA validation across 1,272 participants from multiple centers. Machine learning model trained on extracellular vesicle proteins from both tumor tissue and blood plasma.
Study Limitations
Study conducted primarily in Chinese populations, requiring validation in diverse ethnic groups. Long-term follow-up needed to assess clinical outcomes. Cost-effectiveness compared to existing screening methods not yet established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.